Recently new radiopharmaceuticals have been proposed for investigating prostate cancer patients, including metabolic radiotracer such as anti1-amino-3-18F-fluorocyclobutane-1-carboxylic acid (18F-FACBC) or probe targeting the prostate-specific membrane antigen (PSMA). These radiotracers showed in literature better performance in the detection of prostate cancer recurrence as compared to choline PET/CT imaging [1, 2].
Ceci, F., Morigi, J.J., Zanoni, L., Fanti, S. (2016). New radiopharmaceutical markers for metabolism and receptor. Heidelberg : Springer International Publishing [10.1007/978-3-319-42327-2_9].
New radiopharmaceutical markers for metabolism and receptor
Ceci, Francesco
;Morigi, Joshua James;Zanoni, Lucia;Fanti, Stefano
2016
Abstract
Recently new radiopharmaceuticals have been proposed for investigating prostate cancer patients, including metabolic radiotracer such as anti1-amino-3-18F-fluorocyclobutane-1-carboxylic acid (18F-FACBC) or probe targeting the prostate-specific membrane antigen (PSMA). These radiotracers showed in literature better performance in the detection of prostate cancer recurrence as compared to choline PET/CT imaging [1, 2].File in questo prodotto:
Eventuali allegati, non sono esposti
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
